Skip to main content

Table 1 Characteristic of Patients with CTC detection

From: Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Characteristics

Total

No. patients (%)

P

CTC HER2+

CTC HER2-

Overall

58

22 (37.9)

36 (62.1)

 

Age (years)

    

 Median

48.5

49.0

46.5

0.289

 Range

27–68

29–68

27–65

ER and/or PR

    

 Positive

33

8 (24.2)

25 (75.8)

0.014

 Negative

25

14 (56.0)

11 (44.0)

No. of Metastasis

    

 1

8

5 (62.5)

3 (37.5)

0.238

 ≥ 2

50

17 (34.0)

33 (66.0)

Metastatic sites

    

 Visceral

44

16 (36.4)

28 (63.6)

0.663

 Non-visceral

14

6 (42.9)

8 (57.1)

DFS

    

 ≤ 12

24

12 (50.0)

12 (50.0)

0.111

 > 12

34

10 (29.4)

24 (70.6)

Systemic therapy line

    

 1

7

5 (71.4)

2 (28.6)

0.092

 ≥ 2

51

17 (33.3)

34 (66.7)

Treatment option

    

 Trastuzumab + Chemo

43

19 (44.2)

24 (55.8)

0.096

 Lapatinib + Chemo

15

3 (20.0)

12 (80.0)